Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years.
Elalfy MS, Hamdy M, El-Beshlawy A, Ebeid FSE, Badr M, Kanter J, Inusa B, Adly AAM, Williams S, Kilinc Y, Lee D, Fradette C, Rozova A, Temin NT, Tricta F, Kwiatkowski JL.
Elalfy MS, et al. Among authors: rozova a.
Blood Adv. 2023 Feb 28;7(4):611-619. doi: 10.1182/bloodadvances.2021006778.
Blood Adv. 2023.
PMID: 36018224
Free PMC article.
Clinical Trial.